Meeting
2013 ASCO Annual Meeting
Interim safety analysis of a phase III trial with 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: The AIO-sto-0210 FLOT4 study.
Authors
Claudia Pauligk
Krankenhaus Nordwest, UCT University Cancer Center, Frankfurt, Germany
Claudia Pauligk , Johannes Meiler , Ralf Dieter Hofheinz , Hans-Georg Kopp , Frank Mayer , Harald Schmalenberg , Kim Luley , Georg Martin Haag , Wolff H. Schmiegel , Nils Homann , Stephan Probst , Michael Koenigsmann , Nicole Prasnikar , Jorg Trojan , Matthias Egger , Rolf Mahlberg , Michael Heike , Andrea Tannapfel , Elke Jäger , Salah-Eddin Al-Batran
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT01216644
Citation
J Clin Oncol 31, 2013 (suppl; abstr 4079)
DOI
10.1200/jco.2013.31.15_suppl.4079
Abstract #
4079
Poster Bd #
21A
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO.
First Author: Claudia Pauligk
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).
First Author: Izuma Nakayama
Poster
2017 Gastrointestinal Cancers Symposium
A pilot study of apatinib reversing paclitaxel resistance in heavily pretreated advanced gastric cancer (AGC).
First Author: Rongbo Lin
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Long-term outcomes from adding durvalumab to neoadjuvant treatment of operable gastroesophageal cancers: Results from a multicenter study LUD2015-005.
First Author: Mark R. Middleton